Wird geladen...
5HT-2c AGONIST LORCASERIN DECREASES CANNABIS SELF-ADMINISTRATION IN DAILY CANNABIS SMOKERS
There are no FDA-approved treatments for cannabis use disorder (CUD). Preclinical research has shown that the 5HT-2c agonist, lorcaserin, attenuates cue-induced reinstatement of THC-seeking and self-administration. The goal of this placebo-controlled, counterbalanced, within-subject human laboratory...
Gespeichert in:
| Veröffentlicht in: | Addict Biol |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8225547/ https://ncbi.nlm.nih.gov/pubmed/33389797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/adb.12993 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|